<SEC-DOCUMENT>0001279569-16-004842.txt : 20161214
<SEC-HEADER>0001279569-16-004842.hdr.sgml : 20161214
<ACCEPTANCE-DATETIME>20161214084508
ACCESSION NUMBER:		0001279569-16-004842
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20161214
FILED AS OF DATE:		20161214
DATE AS OF CHANGE:		20161214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37410
		FILM NUMBER:		162050336

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>essa6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Report of Foreign Private Issuer
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of
1934 </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>For the month of December 2016</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Commission File Number 001-37410
</B></P>

<P STYLE="font: 24pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>ESSA Pharma Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Translation of registrant&rsquo;s
name into English) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Suite 720, 999 West Broadway,
Vancouver, British Columbia, Canada, V5Z 1K5 </B></P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of principal executive offices)
</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F </FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> Form 40-F </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBITS
INCLUDED AS PART OF THIS REPORT </B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font: bold 8pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit(s)</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: top; font: 10pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press
                                         Release: ESSA Pharma Provides Business Update and Announces Fourth Quarter and Year Ended
                                         September 30, 2016 Financial Results</FONT></P>


</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">
        <P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt"><B><I>E</I></B></FONT><B><I><FONT STYLE="font-size: 7.5pt">SSA</FONT><FONT STYLE="font-size: 10pt">
        P</FONT><FONT STYLE="font-size: 7.5pt">HARMA</FONT><FONT STYLE="font-size: 10pt"> I</FONT><FONT STYLE="font-size: 7.5pt">NC</FONT><FONT STYLE="font-size: 10pt">.</FONT></I></B></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; font: 10pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
      December 14, 2016</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt">/</FONT><FONT STYLE="font-size: 7.5pt">S</FONT><FONT STYLE="font-size: 10pt">/
        D</FONT><FONT STYLE="font-size: 7.5pt">AVID</FONT><FONT STYLE="font-size: 10pt"> W</FONT><FONT STYLE="font-size: 7.5pt">OOD</FONT></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Name:</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt">Title:</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Wood</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED DECEMBER 14, 2016
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; margin: 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 9.75pt 0"><IMG SRC="image_002.jpg" ALT="Photo_Asset_1" STYLE="height: 148px; width: 400px"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><B>ESSA Pharma Provides Business Update and Announces Fourth
Quarter and Year Ended September 30, 2016 Financial Results</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">HOUSTON and VANCOUVER, Dec. 14, 2016 /CNW/ - ESSA Pharma
Inc. (&quot;ESSA&quot; or the &quot;Company&quot;) (NASDAQ: EPIX, TSX: EPI), a clinical stage pharmaceutical company focused on
developing novel therapies for prostate cancer, today reported financial results for the year ended September 30, 2016 and progress
on its clinical development program.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B><I>2016 Business Highlights</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>Clinical Development</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">&quot;We continue to advance our lead clinical product candidate,
EPI-506, in our Phase 1/2 clinical trial in men with metastatic castrate-resistant prostate cancer (&quot;mCRPC&quot;). This drug,
which we believe works in a novel manner to inhibit androgen-driven pathways in prostate cancer, is being tested initially in men
who have progressed after therapy with current generation anti-androgens,&quot; said David R. Parkinson, MD, President and Chief
Executive Officer.&nbsp;&quot;We are encouraged by the fact that the drug has been shown to be well-tolerated with a predictable
pharmacokinetic profile to-date. We look forward to reporting the clinical results from the study following establishment of a
Phase 2 dose.&quot;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">The clinical trial continues to enroll patients in both the
United States and Canada. Dose escalations have been informed by assessments of patients safety and a pharmacokinetic assessment
of drug exposure.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The study drug has been well tolerated in the clinical
trial with a favorable safety profile to date. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Patients are currently being dosed in the fifth cohort
of the clinical trial. Initial dose selection in the clinical trial was estimated using allometric scaling from animal studies.
Pharmacokinetic data from the clinical trial &nbsp;revealed lower study drug exposures than initially projected. As a result, more
aggressive dose escalations were required. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Pharmacokinetic assessments indicate dose-proportional
exposure of study drug across all cohorts. The Company believes that the current dosing cohort may achieve study drug exposures
similar to exposures associated with the minimally efficacious dose seen in prosate tumor animal models. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">ESSA hopes to establish a Phase 2 dose during calendar
Q1 2017 and to commence the Phase 2 portion of the clinical trial thereafter. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Company has received regulatory clearance from
the UK and French authorities to begin the Phase 2 portion of the clinical trial, pending review of the Phase 1 data.&nbsp; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>About the clinical trial:</B> The Company initiated the
Phase 1/2 clinical trial of EPI-506 in late 2015.&nbsp; The clinical trial is designed to demonstrate the safety, tolerability,
maximum tolerated-dose, pharmacokinetics and efficacy of EPI-506 in the treatment of prostate cancer patients who have failed treatments
using abiraterone or enzalutamide or both, the current standard-of-care drugs in mCRPC.&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">The Phase 1 portion of the clinical trial is an open-label,
adaptive 3 + 3 design, dose-escalation study. Enrolled patients may be allowed to escalate to a subsequent dose cohort after their
initial 12 weeks. In addition to clinical, radiological and biochemical assessments including prostate specific antigen measurements,
patients are being characterized biologically with respect to characteristics known to be associated with resistance to currently
used anti-androgens.&nbsp;These assessments include expression of androgen receptor (&quot;AR&quot;) splice variants in circulating
tumor cells, assessment of AR copy number, and mutations in circulating free DNA.&nbsp;The Phase 1 portion of the clinical trial
is being conducted in 5 institutions in the United States and Canada.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">The Phase 2 portion of the clinical trial will begin following
the establishment of a Phase 2 dose and will be conducted in the United States, Canada, the UK, and France, in patients with prostate
cancer resistant to the newer generation anti-androgens. It is a single-arm, open-label study, with a primary endpoint of number
of patients demonstrating a 50% decline in prostate specific antigen (&quot;PSA&quot;), as well as&nbsp; radiographic progression.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">Additional data about the study can be found at ClinicalTrials.gov.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>Recent Scientific Publications Regarding EPI- Compounds:
&nbsp;</B>In 2016, several important publications were published concerning the biochemical and biological effects of the EPI-
series of compounds, adding to our understanding of their mechanism of action.&nbsp; Published studies have decribed how the EPI
compounds specifically bind to the Tau5 region of the androgen receptor N-terminal domain, thereby uniquely and selectively inhibiting
AR-driven gene transcription, and forming the basis for active inhibition of the AR pathway in men with castrate-resistant prostate
cancer, even in the setting of resistance to currently-used anti-androgens. Further details regarding the publications discussed
herein can be found on the Company's website.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B><I>2016 Year Financial Highlights</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">Amounts disclosed herein, unless specified otherwise, are
expressed in United States dollars and in accordance with International Financial Reporting Standards (&quot;IFRS&quot;). References
to &quot;$&quot; are to United States dollars and references to &quot;C$&quot; are to Canadian dollars.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Receipt of $3.8 million from the Cancer Prevention
and Research Institute of Texas. </B>The approval of the Investigational New Drug (&quot;IND&quot;) application in September 2015
triggered the receipt of an additional $3.8 million of funding from the Cancer Prevention and Research Institute of Texas (&quot;CPRIT&quot;).
Under ESSA's agreement with CPRIT, a total of $12.0 million of grant funding (repayable out of potential product revenues) will
be made available to the Company, of which $2.8 million had previously been received. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Closed $20.0 million in Private Placements</B><I>.
</I>On January 14, 2016 the Company completed a private placement for aggregate gross proceeds of approximately $15.0 million led
by Clarus Lifesciences (the &quot;January 2016 Financing&quot;; see news release dated January 14, 2016). On March 21, 2016, the
Company closed a private placement to Eventide Funds for gross proceeds of $5.0 million (the &quot;March 2016 Financing&quot;;
see news release dated March 21, 2016). </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Receipt of $10.0 million term loan from Silicon
Valley Bank</B><I>. </I>On November 18, 2016, the Company entered into a term loan agreement with Silicon Valley Bank, pursuant
to which the Company has drawn down $8.0 million, with an option for an additional $2.0 million by April 30, 2017, conditional
on positive data from the ongoing Phase 1 clinical trial and receipt of the $5.4 million balance of the grant from CPRIT.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B><I>Summary Financial Results</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Net Income (Loss</B>). ESSA recorded a net loss
of $13.1 million ($0.49 per common share) for the year ended September 30, 2016, compared to a net loss of $9.7 million ($0.53
per common share) for the year ended September 30, 2015. The net loss for the fourth quarter of 2016 was $4.2 million compared
to a net income of $0.5 million for the fourth quarter of 2015. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Research and Development (&quot;R&amp;D&quot;)
expenditures.</B> R&amp;D expenditures for the year were $13.6 million compared to $5.0 million, net of grants ($10.4 million gross),
for the year ended September 30, 2015. For the fourth quarter ended September 30, 2016, R&amp;D expenditures were $3.9 million
compared to a recovery of $0.8 million, net of grants ($3.1 million gross), for the fourth quarter ended September 30, 2015. Increases
in R&amp;D expenditures for the full year and fourth quarter were primarily related to manufacturing and clinical costs as the
Company continues its clinical development of EPI-506. In the quarter ended December 31, 2015, the Company commenced enrolling
patients into its Phase 1/2 clinical trial. The composition of R&amp;D costs has therefore evolved from preclinical and IND application
work in the year ended September 30, 2015 to include clinical, manufacturing and additional staff salaries in the year ended September
30, 2016. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>General and administration (&quot;G&amp;A&quot;)
expenditures.</B> G&amp;A for the year ended September 30, 2016 were $5.6 million compared to $5.3 million for the year ended September
30, 2015. The increase was primarily due to increased activity as a public corporate entity, and additional general and administrative
expenditures to support the clinical development of EPI-506. For the fourth quarter ended September 30, 2016, G&amp;A was $1.2
million compared to $2.2 million for the fourth quarter ended September 30, 2015. The decrease for the fourth quarter was primarily
due to decreased professional, regulatory, and listing fees, which in the prior quarter were incurred in relation to the Company's
initial listings on the NASDAQ and TSX.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B><I>Liquidity and Outstanding Share Capital</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">Working capital as at September 30, 2016 was $6.4 million.
In November 2016, the Company secured a $10.0 million term loan (see news release dated November 21, 2016). Management believes,
assuming completion of the Phase 1 clinical trial in the first quarter of calendar 2017, that the term loan, together with the
Company's existing capital, will provide the Company with sufficient funds to (i) complete EPI-506's Phase 1 clinical trial, (ii)
trigger a $5.4 million grant under the CPRIT program at completion of the Phase 1 clinical trial and (iii) commence EPI-506's Phase
2 portion of the clinical trial.&nbsp; The Phase 1 portion is anticipated to complete in the first quarter of calendar 2017, depending
on the enrollment rate and number of dose escalation steps. Management continues to consider sources of additional financing which
would assure continuation of the Company's operations and research programs.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">As of September 30, 2016, the Company had 29,096,889 common
shares issued and outstanding, 4,062,519 common shares issuable upon the exercise of outstanding stock options at a weighted-average
exercise price of C$2.76 per common share, and 7,099,541 common shares issuable upon the exercise of outstanding warrants at a
weighted-average exercise price of $3.28 per common share.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>About ESSA Pharma Inc.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">ESSA Pharma is a clinical-stage pharmaceutical company focused
on developing novel and proprietary therapies for the treatment of castration resistant prostate cancer (&quot;CRPC&quot;) in patients
whose disease is progressing despite treatment with current therapies. ESSA believes that its product candidate, EPI-506, can significantly
expand the interval of time in which patients suffering from CRPC can benefit from hormone-based therapies. EPI-506 acts by disrupting
the AR signaling pathway, which is the primary pathway that drives prostate cancer growth. EPI-002, the primary metabolite of EPI-506,
prevents AR activation by binding selectively to the N-terminal domain (&quot;NTD&quot;) of the AR. A functional NTD is essential
for activation of the AR. Blocking the NTD prevents activation of the AR by all of the three known mechanisms of activation. In
pre-clinical studies, blocking the NTD has demonstrated the capability to overcome the known AR-dependent mechanisms of CRPC. ESSA
was founded in 2009.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>About Prostate Cancer</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">Prostate cancer is the second-most commonly diagnosed cancer
among men and the fifth most common cause of male cancer death worldwide (Globocan, 2012). Adenocarcinoma of the prostate is dependent
on androgen for tumor progression and depleting or blocking androgen action has been a mainstay of hormonal treatment for over
six decades. Although tumors are often initially sensitive to medical or surgical therapies that decrease levels of testosterone
(for example, ADT), disease progression despite castrate levels of testosterone generally represents a transition to the lethal
variant of the disease (mCRPC) and most patients ultimately succumb to the illness. The treatment of mCRPC patients has evolved
rapidly over the past five years; despite these advances, additional treatment options are needed to improve clinical outcomes
in patients, particularly those who fail existing treatments including abiraterone or enzalutamide, or those that have contraindications
to receive those drugs. Over time, patients with mCRPC generally experience continued disease progression, worsening pain, leading
to substantial morbidity and limited survival rates. In both in vitro and in vivo studies, ESSA's novel approach to blocking the
androgen pathway has been shown to be effective in blocking tumor growth when current therapies are no longer effective.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>Forward-Looking Statement Disclaimer</B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><I>Certain statements in this news release contain forward-looking
information within the meaning of the Private Securities Litigation Reform Act of 1995 and/or Canadian securities laws that may
not be based on historical fact, including without limitation, statements containing the words &quot;believe&quot;, &quot;may&quot;,
&quot;plan&quot;, &quot;will&quot;, &quot;estimate&quot;, &quot;continue&quot;, &quot;anticipate&quot;, &quot;intend&quot;, &quot;expect&quot;
and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements regarding
the Phase 1 clinical trial, including the drug exposures of the current dosing cohort, the anticipated results and the completion
thereof, the Phase 2 clinical trial, including details and anticipated timing thereof, and the expected location and number of
Phase 2 clinical trial centres, the sufficiency of ESSA's funds to execute the Phase 1 portion of the Phase 1/2 clinical trial
and possible future financings by ESSA. </I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><I>Forward-looking statements and information are subject
to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which
may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied thereby.
Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are
inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and
contingencies. In making forward-looking statements, ESSA may make various material assumptions, including but not limited to the
accuracy of ESSA's financial projections and the Phase 1 portion of the Phase 1/2 clinical trial proceeding as expected.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><I>Forward-looking information is developed based on assumptions
about such risks, uncertainties and other factors set out herein and in ESSA's Annual Report on Form 20-F dated December 14, 2016
under the heading &quot;Risk Factors&quot;, a copy of which is available on ESSA's profile on the SEDAR website at www.sedar.com,
ESSA's profile on EDGAR at www.sec.gov, and as otherwise disclosed from time to time on ESSA's SEDAR profile. Forward-looking statements
are made based on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation
to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may
be required by applicable Canadian and United States securities laws. Readers are cautioned against attributing undue certainty
to forward-looking statements.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>ESSA PHARMA INC.</B><BR>
CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION<BR>
Unaudited (<I>Amounts in thousands)</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">As at September 30,</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">2016</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">2015</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Cash</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">8,985</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">1,579</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Prepaid and other assets</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">1,417</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">5,961</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Total assets</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">10,402</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">7,540</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Current liabilities</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">3,630</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">2,091</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Derivative liability&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">7,309</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">993</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Shareholders' equity (deficiency)</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">(537)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">4,456</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Total liabilities and shareholders' equity (deficiency)</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">10,402</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">7,540</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>ESSA PHARMA INC.</B><BR>
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS<BR>
(Unaudited)<BR>
<I>Amounts in thousands, except share and per share data</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Three months</FONT><BR>
<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">ended</FONT><BR>
<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">September</FONT><BR>
<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">30, 2016</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Three months</FONT><BR>
<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">ended</FONT><BR>
<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">September</FONT><BR>
<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">30, 2015</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-top: Black 1pt solid; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Year ended</FONT><BR>
<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">September</FONT><BR>
<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">30, 2016</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-top: Black 1pt solid; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Year ended</FONT><BR>
<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">September</FONT><BR>
<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">30, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>OPERATING EXPENSES</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Research and development</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">3,952</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">(792)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">13,060</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">4,976</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Financing costs</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">31</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">938</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">94</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">General and administration</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">1,237</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">2,178</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">5,644</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">5,259</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Total operating expenses</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">(5,189)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">(1,417)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">(19,642)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">(10,329)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Gain (loss) on derivative liability </FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">1,041</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">1,124</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">6,574</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">(908)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Other items</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">2</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">781</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">79</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">1,560</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Net income (loss) for the year before taxes</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">(4,146)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">488</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">(12,989)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">(9,677)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Income tax expense</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">(91)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">(151)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">-</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Net income (loss) for the year</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">(4,237)</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">488</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">(13,140)</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">(9,677)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Basic and diluted loss per common share</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">(0.15)</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">0.03</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">(0.49)</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">(0.53)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Weighted average number of common shares outstanding</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">26,903,834</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">18,353,018</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">26,903,834</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt Arial, Helvetica, Sans-Serif; padding: 1.5pt; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">18,353,018</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">SOURCE ESSA Pharma Inc</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">%CIK: 0001633932</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information:</B> David Wood, Chief Financial Officer,
ESSA Pharma Inc., T: 778-331-0962, E: dwood@essapharma.com</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">CO: ESSA Pharma Inc</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">CNW 08:30e 14-DEC-16</P>



<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  0" P,# @0# P,$! 0$!0D&!04%
M!0L(" 8)#0L-#0T+# P.$!01#@\3#PP,$A@2$Q46%Q<7#A$9&QD6&A06%Q;_
MVP!# 00$! 4%!0H&!@H6#PP/%A86%A86%A86%A86%A86%A86%A86%A86%A86
M%A86%A86%A86%A86%A86%A86%A86%A;_P  1" "4 9 # 1$  A$! Q$!_\0
M'0 !  (" P$!              <(!@D!! 4# O_$ %$0  $"!0$$! <," 0#
M" ,   $" P $!081!P@2(3$305%A"108(G&!D146,E56@I*5H:+1TR-"4F)R
ME,'2,T-4L5.RPA<D)31&<Y/P@\/A_\0 ' $!  (# 0$!              4&
M @,$!P$(_\0 -A$  @$" @8(!@(# 0$!      $" P0%$1(A,5&1T1,505)A
M<:&Q(C*!P>'P!A0S0O$C0U/_V@ , P$  A$#$0 _ +_0 @! '!Y0!4?4#:QN
MRDWU6:51:%09BGR,^[+RSSX>*W$(44[QPL#B03P$66A@=*5*,IR>;6?85JMC
M=6%648162?CS/(\L'4#Y-6U]%_\ ,C;U#;]Y^G(U]>W'=7KS'E@Z@?)JVOHO
M_F0ZAM^\_3D.O;CNKUYCRP=0/DU;7T7_ ,R'4-OWGZ<AU[<=U>O,>6#J!\FK
M:^B_^9#J&W[S].0Z]N.ZO7F/+!U ^35M?1?_ #(=0V_>?IR'7MQW5Z\QY8.H
M'R:MKZ+_ .9#J&W[S].0Z]N.ZO7F/+!U ^35M?1?_,AU#;]Y^G(=>W'=7KS'
ME@Z@?)JVOHO_ )D.H;?O/TY#KVX[J]>8\L'4#Y-6U]%_\R'4-OWGZ<AU[<=U
M>O,]?3_:CU$NF^J/;;-N6XE55GVI;>2A\E"5* 4K_$ZDY/JC57P6WI4I5')Z
MEX<C91QBXJU(P45K?CS+<(^#%:193DD#G $<:Q:WV'IRI<K5:D9RJ!.13) !
MU\=F_P 0EL?Q$=P,=UKAUQ<ZXK);W^ZSANL0H6^J3S>Y%<[^VMKWJ;BV[7I5
M.H3!/F..I\:F,>E6$#Z)B=HX%0CKJ-M\$0=;&Z\O\:2]61=<.K.IE<4HU*^:
MVM*N;;4T64?1;W1$C"QMH?+37O[D?.]N9_--_OD8M.5"H3:BJ;GYJ8)YEZ86
MO/M)CH4(QV(YW.3VLZT9&)W9"KU:16%255GY90Y%B:<1CV$1@Z<);4F9JI..
MQF3475S5"DE/B-^UU*4\D.S9>3['-X1SSL;6>VFN&7L=$+ZZCLJ/CS,VMW:E
MU8IJD^.3E*JR!U3D@$J/SFBF.2I@MI+8FO)\\SJIXS=QVM/S7(D*UMLA "6[
MCLA21^L]3IT*P/X' /\ FCBJ8!_^<^*_?8[:>.]^'!\RS-H5EFX;8I]<EI>8
M88J4JW,M-S"0EQ*5I"@% $@'!'7%?J0=.HX-[-1/4JBJ04TMIZ48&PZ5P5>F
M4.DO5.KS\M(R<NG>=F)ET-H0.\F,H0E.6C!9LPG.,(Z4GDBO.J.UQ;].=<DK
M(HSE:=3D"=FR6);/:E/PUCZ,3EO@522SK/+P6M\O<A;C&Z<=5)9^.Q<_8A&[
M=HW5NNK4$W(FE,J/!FERR&=WYY"E_>B6I83:4_\ 7/S(FIBMW/\ VR\C ZS=
M]V5=PKJESUF<4>9?J#J_L*L1VPH48?+%+Z(XY5ZL_FDW]6>0XM;B]YQ:EJ/6
MI1)^V-J61K;S.67765[[+KC:NU"RD^T0:3VA-K8>U1[UO*DJ!IEV5R4W>09J
M+J1[-[$:96]&?S03^B-L;BM#Y9M?5F7T#:!U?I) :O.9FD#]2>8:?!])4G>^
MV.6>%V<]L,O+-'3#$[N'^^?GDS.[8VO;WE"E%;MVBU) ^$IDN2JS]JT_9''4
MP&@_DDUZ\CLIXY6C\\4_3F3?L_:_TC5*XW*#+6Y4Z=/-2JIEPK6AUA*$J2GX
M8(.<J&,IB(O<,G:PTW)-9Y>)+66)PNIZ"BT]O@3!$828@! " $ 8EK=?,EIW
MIO4;HFTI<7+HW)5A2L>,/JX-M^L\3V $]4=-I;2N*RIKMV^1S7=Q&WHNH_UE
M6QM@:@ 8][=M'YC_ .9%AZAM^\_3D5_KVOW5Z\SGRP=0/DU;7T7_ ,R'4-OW
MGZ<AU[<=U>O,>6#J!\FK:^B_^9#J&W[S].0Z]N.ZO7F/+!U ^35M?1?_ #(=
M0V_>?IR'7MQW5Z\SCRP;^_6MNV\#GA+_ "_^2'4-#O/TY#KVOW5Z\RYDBZ'Y
M-IX8PXVE7#O&8JS63R+1%YK,^L?#Z( 0!X&J5>1:^G5;N%:PGW-I[SZ<]:TH
M.Z/6K C=;TW5K1AO:--Q5Z*E*>Y,UDJ4M:BMQ14M1WED]9/$GVQZ 4%G$ (
M0 @! " $ ( 0!-VP';WNQKRBIN("F:%(.S1)'#I%_HD>OSUGU1$8U5T+71[S
MR^Y+8-2T[G2W+/[%YR0D=W**@6XJQM9[1<Q*SLS9FGL\$.LJ4U4:PT<E"N1:
M8/:.2E]1X)X\8L6&X2FE5KKR7/D5[$<5:;I4'YOES*INN..NK==6IQQQ14M:
MU%2E$\R2>)/>8LBU;"N-YGY@! " $ ( 0 @#TK,HSUQ7?2J!+@ERJ3S,JG'[
MZPDGU D^J-=6HJ=.4WV+,V4J;J5(P7:\C9](2S,G),RDN@(98;2VVD<DI2,
M>P1Y])MMME_BE%9(QG6/4"A:<6<]<%<=.Z/,EI9O'2S;I'!M /7PR3R R3&^
MUM:ES44(?\.>ZNJ=O3<Y_P#2A.M.J-TZFU\SU=FRB4:63)TUE1#$J.X?K*[5
MGB>X<(N=I94K:.4%K[7VO]W%/NKRK<RSF]78NQ&%QUG(( 0 @! " $ ( MEX
M->W=RF7)=;K9R^\U3V%=R!TB_M6CV16L?J_%"FO,L>!4OAG4?D6DBO%A$ (
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M_P 0C]I>-X]VZ.J+Q86:M:*C_L]O[X%)O[MW-9R[%L_?$CZ.XXA " $ ( 0
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ME4AT+*%)00XDX."K/P1RCHN,9E7MY4G')OMS.>WP>-&O&HI9I=A8*(4FA "
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M]*E<U67O3=2F"ZM.<AL<DH3W)2 D>B+[0HQHTU3CL11:]65:HZDMK/'C::A
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M3ZHC,7J]':26_42>$TM.[B]VLOR.0BF%Q$ ( 0 @! " $ ( 0 @! " /#O\
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ME2R4CU)W1ZHL]"FJ5*,%V(K5>HZE64WVO,\B-IJ$ ( 0!.W@\9GH=>)EG/\
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MKR+77J*E2E-]BS-8SKCCKBG7E%3CBBMQ1ZU$Y)]I,>@I9:D4%O-YGY@?! "
M)FT4VAZKIK8;-L4RU*=-MMONON3#TVXA;JUJR20!@8&!Z (BKO"H7-7I)3:^
MA*6F*2MJ2IQ@F9;Y8US_ ")I'\\[_;'-U!2[[X(Z>OJO<7$>6-<_R)I'\\[_
M &PZ@I=]\$.OJO<7$>6-<_R)I'\\[_;#J"EWWP0Z^J]Q<1Y8US_(FD?SSO\
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5]=_U9E8  X1.$*<P @! " $ ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
